Pr SHEN Baiyong, MD, PhD - National Order of the Legion of Honor: Chevalier -Deputy Director of the National Key Laboratory for Oncogenes and Related Genes - Director of the Shanghai Key Laboratory for Translational Pancreatic Tumor Research -Executive Chairman of the Institute of Translational Medicine at Shanghai Jiao Tong University -Director, Shanghai Digestive Surgery Laboratory - Director, Pancreatic Disease Laboratory, Shanghai Jiao Tong University  School of Medicine (FMUJTS) - Dean of the Sino-French Medical School of FMUJTS -Former President of the Clinical Robotic Surgery Association (CRSA) -Director, Robotic Surgery Division, China Medical Association -Director of the General Surgery Division of the Shanghai Medical Association Editor-in-Chief of the journal "Aging AND Cancer". From 1996 to 1998, he trained as an intern in Pr BELGHITI's visceral surgery department at Beaujon Hospital. Now a Professor of Surgery, he has long been involved in the clinical  treatment of pancreatic cancer, as well as in fundamental research into the onset and development of pancreatic cancer. Under his aegis, the team at Ruijin Hospital's Pancreatic Cancer Center performed the world's largest cohort of robot-assisted minimally invasive pancreatic surgeries and established the surgical standardization process for robot-assisted cephalic duodenopancreatectomy. By retrospectively analyzing their experience, they concluded that 100 surgical cases and 250 surgical cases constitute two key nodes in the learning curve for robotic CPD. They demonstrated the short-term benefits of robotic pancreatic surgery, and were the first in the world to report the oncological benefits of robotic pancreatic surgery. Through multi-omics research, he led the team to optimize the precise treatment plan for pancreatic cancer and explained the mechanism of pancreatic cancer and the microenvironment in tumor initiation and development. Neutrophil subgroups in the pancreatic cancer microenvironment were identified for the first time, and a subgroup of active glycolysis was  associated with poor prognosis of pancreatic cancers. In collaboration with  Pr LAURENT-PUIG's team, they have identified two biomarkers to stratify pancreatic cancer patients who might be better benefited from adjuvant chemotherapy. Using messenger RNA vaccine and TCR-T technology, the team, under his leadership, also carried out the world's first clinical trials of pancreatic cancer immunotherapy. His research has been published in a number of leading medical journals, including Nature Medicine, Gut, Cell Steml Cell, Jama Surgery, Annals of Surgery, EbioMeicine and Lancet Public Health Wesrten Pacific.